Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000
8 Apr 2022 - TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss
5 Apr 2022 - EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit
25 Mar 2022 - UK earnings, trading statements calendar - next 7 days
18 Mar 2022 - IN BRIEF: Faron research sheds light on Covid-linked mutations
14 Mar 2022 - TRADING UPDATES: IOG to cut Gazprom ties; wholesale changes at Donegal
4 Mar 2022 - TRADING UPDATES: BiVictriX expands development; Okyo wins US patent
23 Feb 2022 - Faron upbeat on updated data from cancer treatment study
23 Feb 2022
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an a...
TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
IN BRIEF: Faron research sheds light on Covid-linked mutations
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutatio...
TRADING UPDATES: IOG to cut Gazprom ties; wholesale changes at Donegal
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Allia...
TRADING UPDATES: BiVictriX expands development; Okyo wins US patent
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Faron upbeat on updated data from cancer treatment study
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investi...
Follow the stocks
